BB Principal Investigator/Program Director (Last, first, middle): GAO, SHOU-JIANG DESCRIPTION. State the application's broad, long-term objectives and specific aims, making reference to the health relatedness ofthe project. Describe concisely the research design and methods for achieving these goals. Avoid summaries of past accomplishments and the use of the first person. This description is meant to serve as a succinct and accurate description of the proposed work when separated from the application. If the application is funded, this description, as is, will become public information. Therefore, do not include proprietary/confidenlJal information. D O N OT EXCEED T HE SPA C E P R O V ID ED. Kaposi's sarcoma(KS)-associatedherpesvirus(KSHV/I-IHV8) is a DNA tumor virus etiologically associated with KS and several other malignancies. The applicant's long-range goal is to use KSHV as a paradigm to understand the molecular mechanism of virus-induced pathogenesis, providing biologic basis for preventative and therapeutic purposes. The overall hypothesis is that KSHV encodes specific genes to evade host antiviral defenses and complete viral life cycle. An array of KSHV genes has been shown to deregulate cellular functions when cloned and examined individually. However, their precise functions in viral infection and KSHV-related pathogenesis remain unclear. The lack of an efficient infection model has hampered the investigation of KSHV infection, replication, and genetic manipulation so far. We have recently cloned the entire KSHV genome into a bacteria artificial chromosome (BAC) and reconstituted it in 293 cells. Recombinant virions can infect 293 cells with -100% primary infection efficiency, and establish stable latent infection. Recombinant genomes can also be easily recovered in bacteria. The objective of this application is to develop cellular models for KSHV infection, replication, cellular transformation, and genetic analysis, and to use it to examine functions of viral immediate-early (IE) genes. The central hypothesis is that recombinant KSHV infection of 293 cells and human primary endothelial cells closely mimics the natural viral life cycle, and could be used as cellular models for viral infection and replication. The rationale is that such cellular models are vital for understanding KSHV virology and KSHV-related pathogenesis, and IE genes have critical roles in viral infection and replication. There are three specific aims: 1) To determine the expression patterns of viral and cellular genes, and phenotypic characteristics of recombinant KSHV infection and replication in 293 cells; 2) To infect and transform human primary endothelial cells with recombinant virions, establish stable cell lines, and determine their virology and cellular biology; 3) To define the functions of KSHV IE genes in viral infection, replication, and cellular transformation by examining viral mutants using the cellular models. The proposed work is innovative, because currently there is no efficient cellular model for KSHV infection and genetic manipulation. It is our expectation that these studies will define the virology and cellular biology of KSHV primary infection, latent and lytic replication, cellular transformation and functions of IE genes. These studies will be significant, because they will establish cellular models for examining KSHV infection and functional dissections of individual viral genes, which could provide insight into the pathogenesis of KSHV-related malignancies. The cellular models will also be useful for the development of anti-KSHV vaccines and therapeutic drugs. PERFORMANCE SITE ========================================Section End===========================================

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA096512-03
Application #
6830729
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Read-Connole, Elizabeth Lee
Project Start
2003-01-13
Project End
2007-12-31
Budget Start
2005-01-01
Budget End
2005-12-31
Support Year
3
Fiscal Year
2005
Total Cost
$333,233
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Pediatrics
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Liu, Hui; Wang, Huaizhi; Wei, Zhen et al. (2018) MeT-DB V2.0: elucidating context-specific functions of N6-methyl-adenosine methyltranscriptome. Nucleic Acids Res 46:D281-D287
Tan, Brandon; Liu, Hui; Zhang, Songyao et al. (2018) Viral and cellular N6-methyladenosine and N6,2'-O-dimethyladenosine epitranscriptomes in the KSHV life cycle. Nat Microbiol 3:108-120
Gruffaz, Marion; Zhou, Shenghua; Vasan, Karthik et al. (2018) Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. MBio 9:
Cheng, Fan; Ramos da Silva, Suzane; Huang, I-Chueh et al. (2018) Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol 92:
Jeon, Hyungtaek; Yoo, Seung-Min; Choi, Hyo Sun et al. (2017) Extracellular vesicles from KSHV-infected endothelial cells activate the complement system. Oncotarget 8:99841-99860
He, Meilan; Tan, Brandon; Vasan, Karthik et al. (2017) SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells. J Pathol 242:309-321
Yuan, Hongfeng; Tan, Brandon; Gao, Shou-Jiang (2017) Tenovin-6 impairs autophagy by inhibiting autophagic flux. Cell Death Dis 8:e2608
Li, W; Hu, M; Wang, C et al. (2017) A viral microRNA downregulates metastasis suppressor CD82 and induces cell invasion and angiogenesis by activating the c-Met signaling. Oncogene 36:5407-5420
Yuan, Hongfeng; He, Meilan; Cheng, Fan et al. (2017) Tenovin-6 inhibits proliferation and survival of diffuse large B-cell lymphoma cells by blocking autophagy. Oncotarget 8:14912-14924
Gruffaz, Marion; Vasan, Karthik; Tan, Brandon et al. (2017) TLR4-Mediated Inflammation Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway. Cancer Res 77:7094-7108

Showing the most recent 10 out of 85 publications